Gene: TBC1D22A
Official Full Name: TBC1 domain family member 22Aprovided by HGNC
Gene Summary: Enables 14-3-3 protein binding activity and protein homodimerization activity. Predicted to be active in Golgi apparatus. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO28852 | TBC1D22A Knockout cell line (HeLa) | Human | TBC1D22A | 1:3~1:6 | Negative | Online Inquiry |
KO28853 | TBC1D22A Knockout cell line (HCT 116) | Human | TBC1D22A | 1:2~1:4 | Negative | Online Inquiry |
KO28854 | TBC1D22A Knockout cell line (HEK293) | Human | TBC1D22A | 1:3~1:6 | Negative | Online Inquiry |
KO28855 | TBC1D22A Knockout cell line (A549) | Human | TBC1D22A | 1:3~1:4 | Negative | Online Inquiry |
TBC1D22A Gene Knockout Cell Lines are genetically engineered cells specifically modified to lack the TBC1D22A gene, a significant gene involved in cellular processes such as endosome trafficking and signal transduction. These cell lines serve as a powerful tool for researchers investigating the functional roles of TBC1D22A in various biological contexts, including cell proliferation, differentiation, and apoptosis. By utilizing CRISPR-Cas9 or similar gene editing techniques, these knockout lines facilitate the study of the gene's regulatory mechanisms and its implications in disease models, particularly those related to cellular transport and cancer.
The key mechanism of action for TBC1D22A knockout cell lines lies in the disruption of normal protein interactions and downstream signaling pathways typically mediated by the TBC1D22A protein. This allows researchers to observe changes in cellular behavior, elucidating the specific contributions of TBC1D22A in maintaining cellular homeostasis. As such, these knockout lines are crucial for revealing insights into disease mechanisms and therapeutic targets, making them invaluable in both basic research and clinical research settings.
One substantial advantage of TBC1D22A Gene Knockout Cell Lines over traditional methods is the specificity and efficiency of gene disruption. Unlike chemical inhibitors or RNA interference, which may produce off-target effects, the knockout approach provides a clear and definitive analysis of gene function. Additionally, these cell lines are readily adaptable for high-throughput screening applications, significantly accelerating the pace of research.
Researchers and clinicians value TBC1D22A knockout cell lines for their potential to unlock new avenues in therapeutic development, especially in understanding complex conditions where TBC1D22A is implicated. By leveraging these tools, users can design novel interventions and explore biomarker discovery in their respective fields.
Our company specializes in producing high-quality, reliable biological products backed by rigorous research and quality control. We are committed to advancing the life sciences through innovative offerings like TBC1D22A Gene Knockout Cell Lines, empowering researchers to achieve their scientific goals with precision and confidence.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.